Tonix Pharmaceuticals announces presentations on Tonmya

Tonix Pharmaceuticals (TNXP) announced two oral presentations on Tonmya, which was investigated as TNX-102 SL at the 8th International Congress on Controversies in Fibromyalgia held on March 9-10, 2026, in Krakow, Poland. Oral Presentation One: “Cyclobenzaprine HCl Sublingual Tablets Provide Rapid Pain Relief in Adults with Fibromyalgia.” Tonmya was generally well tolerated, with 6.1% of participants discontinuing due to adverse events versus 3.5% with placebo. The most common treatment-emergent adverse events were oral cavity reactions, including oral hypoesthesia and abnormal product taste, which were typically mild, transient, and self-limited. Oral Presentation Two: “Cyclobenzaprine HCl Sublingual Tablets for the Treatment of Fibromyalgia: Number Needed to Treat and Number Needed to Harm.” The LHH was 3.7, indicating that Tonmya provides a nearly four-fold greater likelihood of clinical benefit than adverse event-related discontinuation. The pooled safety data were consistent with the known profile of Tonmya, with no new or unexpected safety signals. The most common treatment-emergent adverse events were oral cavity reactions that were typically mild, transient, and self-limited.